Comparison of conventional transarterial chemoembolization (cTACE) with doxorubicin drug-eluting bead transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma
- At: 2013 FIP Congress in Dublin (Ireland)
- Type: Poster
- By: HUA, Shih-Chun (Cathay General Hospital, Taipei, China Taiwan)
- Co-author(s): Wu, Shwu-Ying (Cathay General Hospital, Taipei, China Taiwan)
Huang, Wan-Tsui (Cathay General Hospital, Taipei, China Taiwan)
Transarterial chemoembolization (TACE) has been the main treatment for unresectable hepatocellular carcinoma (HCC). Doxorubicin drug-eluting bead transarterial chemoembolization (DEB-TACE) is a newly developed treatment to improve drug delivery with lower systemic toxicity.
This retrospective study aimed to compare the outcomes.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.